Latest Content

In this CME article, explore why migraine often coexists with depression and anxiety, and get practical tips for diagnosis, prevention, and smarter prescribing.

Clearmind patents MDMA plus PEA combo aiming to boost PTSD, anxiety and eating-disorder therapy as FDA issues new psychedelic trial guidance.

FDA acceptance of mitragynine IND launches NIH phase 1 trial for opioid use disorder, tracking safety, dosing, and PK amid new DEA scheduling moves.

Digital reading boosts convenience but weakens comprehension and memory; evidence links “digital amnesia” to shallower learning, making print vital for deep clinical study.

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

A paraplegic psychiatry resident shares integrative chronic pain care: ACT, spinal stimulation, and goals focused on function, not pain scores.

Long-acting injectable buprenorphine cuts missed doses, boosts retention, and protects patients during high-risk transitions in the fentanyl era.

FDA signals clear IND path for PT00114, a first-in-class neuropeptide aiming to reset stress responses in patients with generalized anxiety disorder.

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

Learn why varenicline leads smoking cessation products in bipolar disorder, with reassuring safety data and practical strategies when quitting proves difficult.

Remote, home-based tDCS shows modest symptom relief and higher remission in major depression, with generally good safety but burn risks to watch.

A quick recap of the last week in psychiatric news.

FDA approves PET imaging agent for Alzheimer disease tau pathology.